- Home
- BTAI
as of 12-19-2025 3:43pm EST
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 49.2M | IPO Year: | 2018 |
| Target Price: | $32.80 | AVG Volume (30 days): | 540.0K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.17 - $9.26 | Next Earning Date: | 11-12-2025 |
| Revenue: | $752,000 | Revenue Growth: | -66.96% |
| Revenue Growth (this year): | -72.38% | Revenue Growth (next year): | 416.40% |
AI-Powered BTAI Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Compare BTAI vs Leading Stocks
See how BTAI stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BTAI BioXcel Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.